{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:42:00Z","timestamp":1790883720586,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.healun.2007.01.017","type":"journal-article","created":{"date-parts":[[2007,3,8]],"date-time":"2007-03-08T17:22:25Z","timestamp":1173374545000},"page":"250-257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Calcineurin Inhibitor\u2013Free Immunosuppression Using Everolimus (Certican) in Maintenance Heart Transplant Recipients: 6 Months\u2019 Follow-up"],"prefix":"10.1016","volume":"26","author":[{"given":"Markus","family":"Rothenburger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Teerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Lehmkuhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Suwelack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Bara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wichter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Hinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Stypmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2007.01.017_bib1","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.1016\/j.healun.2004.03.008","article-title":"Calcineurin inhibitors in heart transplantation","volume":"23","author":"Keogh","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2007.01.017_bib2","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1016\/j.transproceed.2005.02.118","article-title":"Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors","volume":"37","author":"Eisen","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.healun.2007.01.017_bib3","unstructured":"Organ Procurement and Transplantation Network reports 1996\u20132001. Available at http:\/\/www.optn.org."},{"key":"10.1016\/j.healun.2007.01.017_bib4","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1016\/j.transproceed.2005.11.053","article-title":"Late acute cardiac allograft rejection: new therapeutic options?","volume":"37","author":"Schweiger","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.healun.2007.01.017_bib5","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1161\/01.CIR.0000150332.42276.69","article-title":"Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs","volume":"110","author":"Lindenfeld","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2007.01.017_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/01.tp.0000189927.70547.ef","article-title":"Hypertension in heart and heart-lung transplanted children: does impaired baroreceptor function play a role?","volume":"81","author":"Dalla Pozza","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2007.01.017_bib7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2165\/00003495-200464080-00005","article-title":"Everolimus","volume":"64","author":"Chapman","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.healun.2007.01.017_bib8","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1111\/j.1600-6143.2005.01063.x","article-title":"Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant recipients","volume":"5","author":"Vitko","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2007.01.017_bib9","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.transproceed.2004.09.026","article-title":"Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab","volume":"37","author":"Kr\u00e4mer","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.healun.2007.01.017_bib10","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/01.TP.0000162437.73886.CD","article-title":"Clinical experience with everolimus (Certican) in young renal transplant recipients","volume":"79","author":"Eris","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2007.01.017_bib11","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1097\/01.TP.0000162431.96893.AE","article-title":"Clinical experience with everolimus (Certican) in elderly recipients: the \u201cold-for-old\u201d concept","volume":"79","author":"Pascual","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2007.01.017_bib12","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1097\/00007890-200505153-00001","article-title":"Reduction in calcineurin inhibitor exposure and maintenance of effective immunosuppression: clinical experience with everolimus (Certican)","volume":"79","author":"Monaco","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2007.01.017_bib13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000164352.65613.24","article-title":"Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study","volume":"80","author":"Lorber","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2007.01.017_bib14","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.transproceed.2004.10.062","article-title":"Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation","volume":"36","author":"Lyster","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.healun.2007.01.017_bib15","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S1053-2498(03)00212-2","article-title":"Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free immunosuppression in a cardiac transplant patient with chronic renal failure","volume":"23","author":"Groetzner","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2007.01.017_bib16","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1016\/j.healun.2004.03.010","article-title":"Optimizing the immunosuppressive regimen in heart transplantation","volume":"23","author":"Eisen","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2007.01.017_bib17","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/j.healun.2005.01.013","article-title":"From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation","volume":"24","author":"Valantine","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2007.01.017_bib18","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1016\/j.healun.2005.01.012","article-title":"Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial","volume":"24","author":"Valantine","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2007.01.017_bib19","doi-asserted-by":"crossref","first-page":"S196","DOI":"10.1016\/j.healun.2005.01.010","article-title":"Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference","volume":"24","author":"Hummel","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2007.01.017_bib20","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1016\/j.healun.2005.01.011","article-title":"Clinical experience with Certican (everolimus) in denovo heart transplant patients at the Deutsches Herzzentrum Berlin","volume":"24","author":"Lehmkuhl","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2007.01.017_bib21","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1016\/j.healun.2005.01.021","article-title":"Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna","volume":"24","author":"Zuckermann","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2007.01.017_bib22","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1016\/j.transproceed.2005.10.005","article-title":"Everolimus (Certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure","volume":"37","author":"Lehmkuhl","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.healun.2007.01.017_bib23","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1097\/00007890-200505153-00008","article-title":"Clinical experience with everolimus (Certican): a summary","volume":"79","author":"Ponticelli","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2007.01.017_bib24","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1097\/01.TP.0000162433.34739.61","article-title":"Clinical experience with Everolimus (Certican): Optimizing dose and tolerability","volume":"79","author":"Pascual","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2007.01.017_bib25","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1097\/01.TP.0000162434.62591.F3","article-title":"Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors","volume":"79","author":"Pascual","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2007.01.017_bib26","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1097\/01.TP.0000162436.17526.0F","article-title":"Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical developments","volume":"79","author":"Neumayer","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2007.01.017_bib27","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/rcm.323","article-title":"High-throughput semi-automated 96-well liquid\/liquid extraction and liquid chromatography\/mass spectrometric analysis of Everolimus (RAD001) and cyclosporine A (CSA) in whole blood","volume":"15","author":"Brignol","year":"2001","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1016\/j.healun.2007.01.017_bib28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.trim.2006.02.001","article-title":"Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients","volume":"16","author":"Schweiger","year":"2006","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.healun.2007.01.017_bib29","doi-asserted-by":"crossref","first-page":"27S","DOI":"10.1016\/S0041-1345(00)00862-9","article-title":"Neoral use in the cardiac transplant recipient","volume":"32","author":"Valantine","year":"2000","journal-title":"Transplant Proc"},{"key":"10.1016\/j.healun.2007.01.017_bib30","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1016\/j.healun.2004.03.009","article-title":"Cardiac allograft vasculopathy after heart transplantation: risk factors and management","volume":"23","author":"Valantine","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2007.01.017_bib31","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/00007890-200504270-00020","article-title":"Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema","volume":"79","author":"Fuchs","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2007.01.017_bib32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.healun.2005.08.022","article-title":"Reversible sirolimus-associated pneumonitis after heart transplantation","volume":"25","author":"Hamour","year":"2006","journal-title":"J Heart Lung Transplant"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249807000368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249807000368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:14:08Z","timestamp":1760948048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249807000368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S1053249807000368"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2007.01.017","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calcineurin Inhibitor\u2013Free Immunosuppression Using Everolimus (Certican) in Maintenance Heart Transplant Recipients: 6 Months\u2019 Follow-up","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2007.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}